PD55-09 SEMINAL VESICAL SPARING CYSTECTOMY IN BLADDER CANCER PATIENTS IS FEASIBLE WITH GOOD FUNCTIONAL RESULTS WITHOUT IMPAIRING ONCOLOGICAL OUTCOMES: A LONGITUDINAL LONG-TERM PROPENSITY-MATCHED SINGLE CENTER STUDY

Abstract

You have accessJournal of UrologyBladder Cancer: Invasive IV (PD55)1 Sep 2021PD55-09 SEMINAL VESICAL SPARING CYSTECTOMY IN BLADDER CANCER PATIENTS IS FEASIBLE WITH GOOD FUNCTIONAL RESULTS WITHOUT IMPAIRING ONCOLOGICAL OUTCOMES: A LONGITUDINAL LONG-TERM PROPENSITY-MATCHED SINGLE CENTER STUDY Gallus Beatus Ineichen, Marc Andre Furrer, Brigitta Gahl, Bernhard Kiss, Silvan Boxler, Beat Roth, and George Niklaus Thalmann Gallus Beatus IneichenGallus Beatus Ineichen More articles by this author , Marc Andre FurrerMarc Andre Furrer More articles by this author , Brigitta GahlBrigitta Gahl More articles by this author , Bernhard KissBernhard Kiss More articles by this author , Silvan BoxlerSilvan Boxler More articles by this author , Beat RothBeat Roth More articles by this author , and George Niklaus ThalmannGeorge Niklaus Thalmann More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002089.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Seminal-vesicle-sparing radical cystectomy (SVS-RC) has been reported to improve short-term functional results without compromising oncological outcomes. There is a lack of data on long-term outcomes after SVS-RC. The aim of this study was to compare oncological and functional outcomes in patients after SVS-RC vs. non-SVS-RC METHODS: Oncological and functional outcomes of 470 consecutive patients after RC and orthotopic ileal reservoir from 2000 to 2017 were evaluated. Stratification included six groups according to nerve-sparing (NS) and SVS status: no sparing (n=55), unilateral NS (n=159), bilateral NS (n=132), unilateral SVS and unilateral NS (n=30), unilateral SVS and bilateral NS (n=45), bilateral SVS and bilateral NS (n=49). Propensity modelling was applied to adjust for preoperative differences. RESULTS: Median follow-up among the entire cohort was 64 months. Among the six groups, our analysis showed no difference in local recurrence-free survival (p=0.173). However, progression free, cancer-specific and overall survival were more favorable in patients with SVS-RC (p<0.001, p=0.006, and p<0.001, respectively). Proportions of patients with erectile function recovery were higher in the SVS-groups at all time points in all analyses, respectively, with pronounced earlier recovery in patients with bilateral SVS. Importantly, patients with SVS were significantly less in need of erectile aids to achieve erection and intercourse. Over the whole observation period, daytime urinary-continence was significantly better in the SVS groups (OR 2.64 to 5.21). CONCLUSIONS: In a highly selected group of patients, SVS-RC is oncologically safe and results in excellent functional outcomes that are reached at an earlier timepoint after surgery and remain superior over a longer period of time. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e1000-e1001 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Gallus Beatus Ineichen More articles by this author Marc Andre Furrer More articles by this author Brigitta Gahl More articles by this author Bernhard Kiss More articles by this author Silvan Boxler More articles by this author Beat Roth More articles by this author George Niklaus Thalmann More articles by this author Expand All Advertisement Loading ...